INTRODUCTION
Neuropathic pain is of serious clinical concern, ~5% of the European population being severely affected [1, 2] . It can be spontaneous, stimulus-evoked, or a combination of both [3] . It is not only an economic burden, but also disrupts social activities and reduces the quality of life.
Although neuropathic pain is generally associated with infl ammation and tissue injury, the underlying mechanism is still poorly understood and no effective treatments have been developed. It is estimated that only about half of the patients with neuropathic pain can achieve partial relief with currently-available treatments [4] . Thus, it is imperative to understand its causes and fi nd new therapeutic targets.
Recently, accumulating evidence has suggested that dysregulated cell-surface trafficking of receptors that facilitate pain plays an important role in the development of inflammatory and neuropathic pain [5, 6] . These include potent analgesic effects in rats with neuropathic pain. These fi ndings strongly support the recent hypothesis that targeting receptor trafficking could be a new strategy for the treatment of neuropathic pain.
Keywords: periaqueductal grey; AMPA receptor; GluA 2-3y ; internalization; morphine; hindpaw withdrawal latency subunits of voltage-gated Ca 2+ channels, GluA1 and GluA2 of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), and NR1 and NR2 of N-methyl D-aspartate receptors [5] . It has been shown that peripheral inflammation evoked by intraplantar injection of complete Freund's adjuvant (CFA) increases GluA1 insertion into the cell surface [7] and increases synaptic GluA2 internalization in spinal dorsal horn neurons [8] . Furthermore, L5 and L6
spinal nerve ligation-induced neuropathic pain was found to increase GluA2 internalization in the spinal cord [9] . However, the cell-surface traffi cking of receptors that facilitate pain at the supraspinal level has received little attention.
The periaqueductal grey (PAG) is the grey matter located around the cerebral aqueduct within the midbrain tegmentum [10] . The PAG is an important structure for the transmission and/or modulation of nociceptive information, and is a key station in the analgesia pathway from the brainstem to the spinal cord [11] . GluA 2-3y is a synthetic peptide derived from the rat GluA2 carboxyl tail ( 869 YKEGYNVYG 877 ), and it specifically blocks GluA2-dependent AMPAR internalization [12] . To facilitate intracellular delivery of the peptide, GluA 2-3y was fused with the cell membrane transduction domain of the HIV-1 Tat protein (YGRKKRRQRRR) to generate Tat-GluA 2-3Y , which has been shown to be cell-permeable [12] . The present study was performed to explore the antinociceptive effects of i ntra-PAG delivery of Tat-GluA 2-3y in intact rats and in rats with neuropathic pain. The nerve injury model was produced as previously reported [13] . Rats were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg/kg) and 8 The Randall Selitto and hot-plate tests were performed after sciatic nerve ligation as described previously [14] . In the hot-plate test, the entire ventral surface of the left or right hindpaw was placed on a hot-plate maintained at 52 ± 2°C, and the time to hindpaw withdrawal was measured in seconds and referred to as the h indpaw withdrawal latency 
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RESULTS AND DISCUSSION
In intact rats, the HWLs to thermal and mechanical stimulation increased in a dose-dependent manner after intra-PAG injection ( Fig. 1)(see supplementary data for statistics). These results demonstrated that intra-PAG injection of GluA 2-3y has antinociceptive effects in intact rats, and suggested that GluA2 internalization modulates the pain response in the PAG.
To assess the anti-nociceptive effect of GluA 2-3y on neuropathic pain, we performed sciatic nerve injury in rats.
A group of eight rats received left common sciatic nerve injury. Ten days after injury, thermal hyperalgesia and mechanical allodynia were detected on the left but not the right side (Fig. 2) , suggesting that the mononeuropathic pain model had been created successfully.
The HWLs to thermal and mechanical stimulation increased in a dose-dependent manner after intra-PAG injection ( Fig. 3 ) (see supplementary data for statistics).
Interestingly, intra-PAG injection of GluA 2-3y had a much stronger anti-nociceptive effect on the left side where rats had received sciatic nerve injury, suggesting that GluA2 internalization in the PAG might play a critical role in neuropathic pain.
We then compared the anti-nociceptive effect of GluA 2-3y with that of morphine. Ten micrograms (35 nmol) of morphine was used, as this dose has been shown to have a potent anti-nociceptive effect when microinjected into the PAG, while concentrations <1 μg (3.5 nmol) have no antinociceptive effect [15] . Intra-PAG injection of 15 pmol GluA 2-3y had an anti-nociceptive effect similar to 10 μg morphine on the left side where rats received sciatic nerve injury (Figs.
and 4). These results suggested that administration of
GluA 2-3y in the PAG has a potent analgesic effect at a low concentration in rats with neuropathic pain.
AMPARs are widely expressed in the central nervous system, and the great majority exist as heteromers containing GluA2. GluA2 is a critical subunit controlling AMPAR functions such as Ca 2+ permeability and synaptic plasticity [16] . Over the last five years, increasing evidence has suggested that cell-surface trafficking of GluA2 plays an important role in pain modulation at the spinal level [5] .
In the current study, we showed that blocking GluA2 internalization with GluA 2-3y in the PAG had anti-nociceptive effects in normal rats and in rats with neuropathic pain induced by sciatic ligation, suggesting that GluA2 traffi cking is involved in pain responses at the supraspinal level. Furthermore, GluA 2-3y had much stronger antinociceptive effects in rats with neuropathic pain than in normal rats. Although it is interesting that GluA 2-3y had less effect on the normal side after mononeuropathy, it should be noted that the normal side was not as hypersensitive as the neuropathic side. The response to pain of the normal side after mononeuropathy was similar to normal rats as suggested by our results (Fig. 2) , thus it is reasonable that the normal side is less sensitive to drug treatments, consistent with our previous study [17] .
Based on these results, we assume that sciatic nerve spinal cord [9] . Consistently, another group reported that CFA-induced peripheral inflammation induces synaptic GluA2 internalization in dorsal horn neurons during the maintenance of nociceptive hypersensitivity [8] . We also found that sciatic nerve ligation did not change the total protein level of GluA2 in the PAG (data not shown), consistent with a report showing that the expression of the GluA2 subunit of AMPAR in the ventrolateral PAG does not change after spinal nerve ligation-induced neuropathic pain [18] . These results indicated that GluA2 undergoes dynamic traffi cking between the cell membrane and the cytosol under various conditions such as infl ammation and nerve injury.
Although the PAG is known to be the primary control center for descending pain modulation, it is still not this was demonstrated by the anti-nociceptive effects of intra-PAG injection of GluA 2-3y which specifically blocks GluA2 internalization. We further compared the antinociceptive effects of GluA 2-3y with morphine, which is the most prescribed opioid for pain relief, although the sideeffects (such as addiction) limit its use. It is well known that the PAG-ventromedial medulla-spinal cord pathway is essential for the analgesic actions of both systemic and intra-PAG morphine [19] . We showed that intra-PAG injection of 15 pmol GluA 2-3y produced an analgesic effect similar to 35 nmol morphine in rats with neuropathic pain induced by sciatic nerve ligation. That GluA 2-3y was able to achieve pain relief at this low concentration suggested that drugs targeting GluA2 traffi cking such as GluA 2-3y could be useful in the treatment of persistent pain.
In conclusion, the results of the present study 
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